WO2018062354A1 - Agent d'amélioration du microbiote intestinal et composition d'amélioration du microbiote intestinal qui comprend une poudre contenant une membrane de coquille d'œuf - Google Patents

Agent d'amélioration du microbiote intestinal et composition d'amélioration du microbiote intestinal qui comprend une poudre contenant une membrane de coquille d'œuf Download PDF

Info

Publication number
WO2018062354A1
WO2018062354A1 PCT/JP2017/035121 JP2017035121W WO2018062354A1 WO 2018062354 A1 WO2018062354 A1 WO 2018062354A1 JP 2017035121 W JP2017035121 W JP 2017035121W WO 2018062354 A1 WO2018062354 A1 WO 2018062354A1
Authority
WO
WIPO (PCT)
Prior art keywords
eggshell membrane
intestinal flora
powder
composition
improving
Prior art date
Application number
PCT/JP2017/035121
Other languages
English (en)
Japanese (ja)
Inventor
長谷部　由紀夫
Original Assignee
株式会社 アルマード
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2016190536A external-priority patent/JP7086517B2/ja
Priority claimed from JP2016190537A external-priority patent/JP2018052855A/ja
Application filed by 株式会社 アルマード filed Critical 株式会社 アルマード
Publication of WO2018062354A1 publication Critical patent/WO2018062354A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an intestinal flora improving agent and a composition for improving intestinal flora containing eggshell membrane-containing powder or fine powder as an active ingredient. Further, the present invention relates to a composition for improving intestinal flora and promoting the formation of type III collagen, which comprises eggshell membrane-containing powder or fine powder and a hydrolyzed eggshell membrane component.
  • the eggshell membrane is a membrane inside the eggshell of avian egg such as a chicken egg and consists of 2 sheets inside and outside, the outer shell membrane is in close contact with the inner surface of the eggshell, and the inner shell is wrapped in egg white and has antibacterial properties , Protecting developing embryos from infection.
  • Eggshell membrane has a network-like structure composed of type I, type V and type X collagen, glucosamine, desmosine and tough fibrous proteins mainly composed of hyaluronic acid, and these proteins contain cysteine Are relatively stable to acids, alkalis, and proteases, and insoluble in water.
  • eggshell membrane powder is pulverized using a jet mill so that the volume average particle size is 6 ⁇ m or less or the volume maximum particle size is 20 ⁇ m (800 mesh) or less. It has been proposed to powderize (patent document 1).
  • hydrolyzing hydrolyzed eggshell membrane obtained by hydrolyzing protein is dried and powdered for improvement of handling property and storage stability (Patent Document 2), and alkalinity It has been proposed to increase the storage stability and safety by setting the pH of the hydrolyzed eggshell membrane powder to 3 to 6 (Patent Document 3).
  • the present invention is highly safe, can be used daily as a food additive, food and drink, supplement, medicine as a simple and convenient method, and intestinal flora that can improve or maintain the living body in a good condition with a single material.
  • An object of the present invention is to provide a remedy or a composition for improving intestinal flora.
  • it has a function to promote the formation of type III collagen, and provides a composition capable of improving and / or maintaining the living body in a better state by the synergistic effect of both functions. To be an issue.
  • Eggshell membrane or hydrolysed eggshell membrane is not only for skin softening, skin regeneration, hair growth promotion, hair loss prevention, etc., but also for daily health promotion and health maintenance such as elimination of stiff shoulder, enhancement of appetite, fatigue recovery, etc. It is considered to be effective.
  • eggshell membrane-containing fine powder Patent Document 1
  • hydrolyzed eggshell membrane powder Patent Documents 2 and 3
  • Eggshell membrane-containing fine powder (patent document 1) and hydrolyzed eggshell membrane powder are known to have a function of promoting the formation of type III collagen in the body when digested and absorbed in the body There is.
  • the hydrolyzed eggshell membrane is almost 100% digested and absorbed in the blood, the eggshell membrane-containing powder and fine powder remain in the intestine without digestion and absorption of about 54%.
  • the remaining components prevent the growth of bad bacteria among enteric bacteria and improve the enteric flora, and have completed the present invention.
  • a hydrolyzed eggshell membrane component having a function of further promoting the formation of type III collagen and an eggshell membrane-containing powder or fine powder, than an eggshell membrane-containing powder or fine powder which is only about 46% digested and absorbed
  • the function to improve the internal flora and the function to promote the formation of type III collagen act synergistically to improve the immune function by improving the intestinal flora, and to prevent the development of adult diseases such as cancer, as well as to promote the generation of type III collagen
  • the strengthening of blood vessel, lung, liver and skin tissues has resulted in the completion of a composition that has an enhanced anti-aging effect and can further improve and / or maintain good health.
  • the present invention is summarized as an intestinal flora improving agent containing an eggshell membrane-containing powder as an active ingredient.
  • the present invention also provides a composition for improving intestinal flora, which comprises an eggshell membrane-containing powder as an active ingredient.
  • mice challenged with colitis with DSS after ingestion of eggshell membrane-containing fine powder supplementation prevalence of enterobacteria The result after 17 days by the oral intake experiment of the hydrolysis eggshell membrane powder supplement using a mouse. The expression level in skin of a type III collagen gene by real time PCR is shown.
  • enteric bacteria Hundreds of enteric bacteria are inhabited in a balanced manner in human intestine in a balance of about 100 trillion or more.
  • useful bacteria such as lactic acid bacteria and bifidobacteria (good bacteria) such as E. coli and clostridial bacteria Harmful bacteria (bad bacteria) and opportunistic bacteria form a kind of ecosystem (gut flora) while maintaining balance with each other in the intestine.
  • the enteric flora improvement agent which can be ingested easily and routinely can be provided in various uses, such as a food additive, food-drinks, a supplement, and a pharmaceutical.
  • the intestinal flora improving agent of the present invention is nonirritating, can be used in various forms in combination with various components, and can be easily tableted. It can also be used in combination with nutritional and cosmetic ingredients to obtain further systemic effects.
  • the intestinal flora improving function of the eggshell membrane-containing powder or fine powder and the function of promoting the formation of type III collagen and the hydrolyzed eggshell membrane component acts synergistically to enhance the skin-beautifying effect and anti-aging effect by promoting the formation of type III collagen in blood vessels, lungs, liver, skin etc. and improving intestinal flora. Health condition can be improved and / or well maintained.
  • This composition can be used in various forms as food additives, food and drink, supplements, edible cosmetic agents and medicines, and when hydrolyzed eggshell membrane powder is used as the hydrolyzed eggshell membrane component, tableting is easy. Can be done.
  • the intestinal flora improving agent or composition for improving intestinal flora according to the present invention contains eggshell membrane-containing powder as an active ingredient, and in experiments using rats, 46% of ingested eggshell membrane-containing fine powder is digested Absorbed, the rest remained in the intestine without absorption. It is demonstrated in Example 1 that this remaining component can increase intestinal bacterial diversity and reduce the number of pathogenic bacteria such as E. coli.
  • any membrane can be used as long as it is inside the eggshells of all terrestrial egg live animals, particularly avian eggs.
  • eggshell membranes of hen eggs are preferable in terms of availability and cost.
  • the eggshell membrane-containing powder used in the present invention is not particularly limited as long as it is a powder containing at least an eggshell membrane, and the powder refers to any powder regardless of the particle size.
  • the raw material in a state in which the eggshell membrane is attached to the exfoliated eggshell membrane or eggshell may be powdered by any known method. Alternatively, a commercially available eggshell membrane-containing powder may be used.
  • the eggshell membrane-containing fine powder to be used in the present invention refers to powder having a volume maximum particle size and / or a volume average particle size smaller than about 100 ⁇ m.
  • “volume average particle diameter” and “volume maximum particle diameter” of powder or fine powder mean values measured using a laser diffraction type particle size distribution analyzer (manufactured by Seishin Co., Ltd., LMS-30). Do. When measuring the particle size, a measurement sample in which eggshell membrane-containing fine powder is dispersed in water using a surfactant is used.
  • volume average particle diameter means the particle diameter in 50% of the cumulative value from the small particle diameter side in particle size distribution.
  • eggshell membrane-containing fine powder to be used in the present invention one having a volume average particle size of 6 ⁇ m or less, or a volume maximum particle size of 20 ⁇ m or less is particularly preferable from the viewpoint of digestive and absorption efficiency. It is preferable to manufacture eggshell membrane containing raw materials, such as a commercially available eggshell membrane containing powder, by a pulverization process using a jet mill in which they collide with each other in gas.
  • the hydrolyzed eggshell membrane component used in the present invention is a solution having a protein degrading action such as an aqueous acid solution, an alkaline aqueous solution, an alkaline organic solvent solution, and a proteinase-containing solution, as the eggshell membrane or the aforementioned eggshell membrane-containing powder It is obtained by hydrolysis in vacuo. Although it can also be used as an aqueous solution or an extract, it is preferably in the form of a powder obtained by a drying means such as spray drying or lyophilization for handling and storage stability. As the hydrolyzed eggshell membrane powder, a powder having a pH of 3 to 6 is particularly preferable in view of storage stability and safety.
  • the human skin is composed of an epithelial layer on the surface and a connective tissue-like dermal layer below it, and the protein constituting the dermal layer is mainly collagen, and is also composed of elastin, albumin, globulin and mucin.
  • Collagen constituting the dermal layer is mainly ⁇ 1 (I) collagen and ⁇ 1 (III) collagen (hereinafter referred to as "type III collagen"), type I collagen mainly maintains the skin structure, type III collagen It plays different functions mainly from the application of skin softness.
  • type III collagen is also called fetal collagen, it is most abundant in the case of the fetus and more in the case of fetal skin with type III collagen, but begins to decrease from the 10s and continues to decrease, so type III collagen in the skin If you can increase the rate of aging, you can stop the aging of the skin with age and make the skin smooth and moist.
  • type III collagen is contained in connective tissues such as blood vessels, lungs and liver.
  • the eggshell membrane-containing fine powder not only promotes the formation of type III collagen in the skin but also promotes the generation of type III collagen in blood vessels by the amino acid component that is absorbed and absorbed and absorbed into the blood by about 46%.
  • the elasticity of the whole blood vessel can be increased, and fibrosis can be suppressed even in the liver.
  • About 46% of the eggshell membrane-containing fine powder is digested and absorbed, and about 100% of the hydrolyzed eggshell membrane component is digested and absorbed, and the eggshell membrane component taken up into the blood only promotes the formation of type III collagen in the skin
  • the blood vessels can promote the formation of type III collagen to increase the elasticity of the whole blood vessels, but also can suppress fibrosis in the liver.
  • Both the eggshell membrane component-containing powder and the hydrolyzed eggshell membrane component used in the present invention have a function to promote the formation of type III collagen when digested and absorbed, but the hydrolyzed eggshell membrane component is almost 100% digested and absorbed. Was found to be more effective.
  • the combined use of the eggshell membrane component-containing powder and the hydrolyzed eggshell membrane component not only enhances the formation promoting effect of type III collagen, but also combines with the improvement effect of intestinal flora to synergistically make the skin beautify and prevent aging
  • the composition preferably contains 10 to 90% by weight of eggshell membrane-containing fine powder and 90 to 10% by weight of hydrolyzed eggshell membrane powder.
  • the composition of the present invention can be an oral composition such as tablets, powders, granules, capsules, solutions and the like.
  • oral compositions such as tablets, powders, granules, capsules, solutions and the like.
  • various components and production methods for producing oral compositions of various dosage forms are appropriately selected from components known in the field of production of supplements, pharmaceuticals, etc. be able to.
  • the content of the eggshell membrane-containing powder contained in the tablet of the present invention is not particularly limited, but the total of the eggshell membrane-containing powder and the hydrolyzed eggshell membrane powder contained in the tablet of the present invention
  • the content of.) Is not particularly limited, but the granulation and tableting to particles can be smoothly performed, and the intestinal flora improving effect and the type III collagen formation promoting effect are further enhanced when the tablet is ingested, etc.
  • excipient a binder, a disintegrant, a lubricant, other nutrients, etc. can be added to the tablet of this embodiment as various additives for forming a tablet.
  • excipient known excipients can be appropriately used, but at least one of modified starch and lactose may be used in an amount of 0.3 to 3 times the weight of the eggshell membrane component from the viewpoint of formability. Preferably, it is more preferably 1 to 2.5 times.
  • modified starch one or more kinds of dextrin such as roasted dextrin, oxidized starch, low viscosity modified starch and the like can be used.
  • the use ratio is preferably 1: 5 to 5: 1.
  • known binders can be suitably used, and examples thereof include starch paste, gum arabic paste, hydroxypropyl cellulose and the like.
  • disintegrant known disintegrants can be suitably used, and for example, celluloses can be used.
  • lubricant known lubricants can be appropriately used, and examples thereof include magnesium stearate, sucrose fatty acid ester, waxes, talc, vitamin C and the like.
  • the tablet of the present embodiment preferably contains eggshell calcium as a hardness improver in order to increase the hardness of the tablet to prevent deformation and damage and to improve the handleability.
  • Eggshell calcium is a fine powder obtained by crushing and drying eggshells of birds such as chicken eggs, and the content of eggshell calcium contained in the tablet is preferably 0.1 to 20% by weight, more preferably 0.5 to It is 15% by weight.
  • a well-known coating film can be used suitably for a coating film, For example, brand name "sealac" (made by Gifu shellac KK) can be used.
  • the tablet of the present embodiment may be coated with a sugar coating, may be colored, and may be subjected to polishing after coloring.
  • the size of the tablet of the present embodiment is not particularly limited, but in general, it is preferable from the viewpoint of handleability and ease of administration that the tablet has a circular or oval shape with a diameter of about 7 to 10 mm.
  • the weight of one tablet is about 350 to 600 mg, and the eggshell membrane component is preferably contained in about 10 to 240 mg, more preferably about 20 to 150 mg. If the eggshell membrane component is contained in an amount of about 10 to 240 mg, the adult can take 1 to 200 tablets per day (10 to 48,000 mg of eggshell membrane component per day).
  • the tablet of this embodiment can be manufactured by a known tablet manufacturing method using a raw material for tableting containing at least eggshell membrane-containing fine powder and hydrolyzed eggshell membrane powder. For example, through a tableting process of forming raw tablets by tableting to form a plain tablet, if necessary, a granulation process, a protective coating process, a sugar coating process, etc. are performed, and further coloring and polishing are performed. It is also good.
  • the effective dose of the pharmaceutical preparation as the intestinal flora improving agent of the present invention, the effective dosage of the pharmaceutical as the composition for intestinal flora improvement of the present invention, the degree of symptoms to be treated or prevented, administration It varies according to the condition (including age and gender) and dosage form of the subject.
  • the oral dose of such a medicament to a human is preferably 1 to 100,000 mg per day, in terms of eggshell membrane components.
  • the effective dose can be a total of 10 to 48,000 mg of eggshell membrane components per day, preferably, 20 to 3,500 mg. Since the eggshell membrane-containing component of the present invention is highly safe and there is no concern about side effects, there is no problem if the amount taken or applied exceeds the above range, as long as other components are appropriately selected.
  • composition of the present invention can be a food additive such as confectionery, beverage, health food, preserved food, processed food and the like.
  • the subjects of “pharmaceutical” and “food and drink” are not limited to humans, but also include pharmaceuticals and feeds for mammals such as pets and livestock.
  • the concept of "food and drink” includes enteral nutrition food, nutritive function food, functional display food, food for specified health use, etc. in addition to ordinary food and drink.
  • the volume maximum particle size is 19.6 ⁇ m
  • the volume average particle size is 5.8 ⁇ m (hereinafter referred to as It is called "800 mesh fine powder”.
  • mice Normal control mice (CON group) were fed with AIN-93G basal regular diet and normal drinking water throughout the course of the experiment. 8% eggshell membrane 800 mesh fine powder fortified feed was adjusted with corn starch and casein to maintain calories and protein balance.
  • the disease activity index (DAI) was monitored daily from the day of receiving DSS water, using three scores of mouse weight, stool firmness and blood stool.
  • mice in the DSS group had the lowest bacterial species abundance among the three groups ( Figure 2). This result was as expected, as the bacterial species in the gut is reduced, correlating with disease states including inflammatory bowel disease in humans and DSS-induced colitis in mice, but surprisingly, the eggshell membrane The intake restored the bacterial species abundance to the same extent as the CON group.
  • Enterobacteriaceae which is a marker of enteritis and a marker of oxidative stress in human inflammatory bowel disease and mouse colitis, are more susceptible to the inflammatory DSS group (Proteobacteri all bacteria) compared to the CON group. 39% of the) were detected very frequently. In contrast, Enterobacteriaceae was detected very rarely in the D-ESM 8 group (about 6%). Similarly, DSS administration increased the number of Enterococcaceae but was lowered to near normal levels by eggshell membrane fine powder supplementation.
  • SCFA short-chain fatty acids
  • Quantitative real-time PCR analysis was performed as follows. Back skin and liver samples were taken from each mouse and ground in liquid nitrogen. After homogenization of whole skin tissue or whole liver tissue, total RNA was isolated and cDNA synthesis was performed using a trade name "Takara PrimeScript RT reagent kit”. The real time PCR method was performed using a brand name "SYBR Premix Ex Taq II (Takara) on Thermal Cycler Dice Real Time System” (Takara). As a primer, a primer designed for amplification of a gene encoding Col3a1 (collagen type III) was used.
  • the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was similarly amplified.
  • the PCR cycle was 30 cycles of initial denaturation at 95 ° C. for 30 cycles (denaturation at 95 ° C. for 5 seconds, annealing and elongation at 60 ° C. for 1 minute).
  • a sugar coating paste A (70 parts by weight of granulated sugar, 3 parts by weight of gum arabic, 4 parts by weight of gelatin, 3 parts by weight of eggshell calcium, and the like on a surface of the sufficiently dried protected coated tablet)
  • the paste was mixed with 65 parts by weight of water and then dried at a temperature of 40 ° C. for about 4 hours. Thereafter, a sugar coating paste B obtained by diluting sugar coating paste A with water was coated using a sugar coating apparatus, and then dried at a temperature of 40 ° C. for 4 hours to obtain sugar coating coated tablets.
  • a coloring agent containing the trade name "SR Red K3" (manufactured by San-Ei Gen Co., Ltd.) is applied to the surface of a sugar-coated tablet and dried at 40 to 50 ° C to produce a red-colored tablet. Glossing was performed using carnauba wax. The weight of one tablet thus obtained was 400 mg and contained about 80 mg of eggshell membrane component per tablet. The glazed tablets were screened to remove any defects, weighed after product inspection, and packaged in a double bag enclosed with a desiccant. The tablets had sufficient hardness and shape retention, and did not deform or disintegrate during sorting, inspection or packaging, and were excellent in handleability.
  • the present invention is (1) an intestinal flora improving agent containing an eggshell membrane-containing powder as an active ingredient, (9) a composition for improving intestinal flora, which comprises an eggshell membrane-containing powder as an active ingredient.
  • An improvement composition can be provided.
  • the intestinal flora improving agent and the composition for improving intestinal flora according to the present invention are non-irritating, can be used in various forms in combination with various components, and have nutritional and cosmetic components in order to obtain further systemic effects.
  • the effect is that it can be used in combination with
  • the intestinal flora improving function of the eggshell membrane-containing powder or fine powder and the function of promoting the formation of type III collagen and the hydrolysis eggshell membrane component have III
  • the synergistic effect with the type-collagen formation promoting function promotes the production of type III collagen in blood vessels, lungs, liver, skin, etc., and the improvement of intestinal flora to enhance the beautifying effect and anti-aging effect, and health
  • the condition can be improved and / or well maintained.
  • This composition can be used in various forms as food additives, food and drink, supplements, edible cosmetic agents and medicines, and when hydrolyzed eggshell membrane powder is used as the hydrolyzed eggshell membrane component, tableting is easy.
  • the enteral flora improving agent according to any one of (1) to (3) which is a preparation to be administered orally.
  • the intestinal flora improving agent according to any one of (1) to (4) which is a food additive, food and drink, a supplement or a medicine.
  • the intestinal flora improving agent according to (4) wherein the preparation is a tablet.
  • Intestinal flora improvement is due to the component remaining in the intestine without being absorbed in the intestine increasing the diversity of intestinal bacteria and decreasing the number of pathogenic bacteria, (1) to The intestinal flora improvement agent in any one of (7).
  • the component which is not absorbed and remains in the intestine in the intestine increases the diversity of intestinal bacteria and decreases the number of pathogenic bacteria, (9) to The composition for intestinal flora improvement in any one of (18).
  • an intestinal flora improving agent containing an eggshell membrane-containing powder or a fine powder which is nonirritating and can be used in various forms and in combination with various components.
  • This preparation can be used in various applications and forms such as food additives, food and drink, supplements, medicines, etc., and can be easily taken on a daily basis.
  • a composition for improving intestinal flora containing eggshell membrane-containing powder or fine powder which is nonirritating and can be used in various forms and in combination with various components.
  • the intestinal flora improving function possessed by the eggshell membrane-containing fine powder, the function promoting formation of type III collagen, and the function promoting formation of type III collagen possessed by the hydrolyzed eggshell membrane component It acts synergistically to promote the formation of type III collagen in blood vessels, lungs, liver, skin, etc. and to improve intestinal flora, thereby enhancing skin-beautifying effects and anti-aging effects, improving health and / or Or it becomes a composition which can be maintained well.
  • This composition can be used in various applications and forms such as food additives, food and drink, supplements, edible cosmetic agents, medicines and the like, and can be easily ingested on a daily basis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Le problème décrit par la présente invention est de préparer un agent d'amélioration du microbiote intestinal qui comprend une poudre ou une fine poudre qui contient une membrane de coquille d'œuf. La présente invention concerne également la préparation d'une composition destinée à améliorer le microbiote intestinal et à favoriser la croissance du collagène de type (III) qui utilise à la fois l'agent d'amélioration du microbiote intestinal et un constituant membranaire de coquille d'œuf hydrolysé. La solution selon l'invention porte sur une poudre contenant une membrane de coquille d'œuf, en particulier, une fine poudre contenant une membrane de coquille d'œuf ayant une taille de particule moyenne en volume non supérieure à 6 µm ou une taille de particule maximale en volume non supérieure à 20 µm est efficace comme agent d'amélioration du microbiote intestinal. Une préparation qui comprend cet agent d'amélioration du microbiote intestinal peut être utilisée pour une diversité de buts et dans une diversité de formes, par exemple comme additif alimentaire, produit alimentaire ou de boisson, complément alimentaire, ou agent pharmaceutique. En outre, une composition qui comprend un constituant membranaire de coquille d'œuf hydrolysé améliore les capacités favorisant la croissance du collagène de type (III), fonctionne en synergie avec des effets d'amélioration du microbiote intestinal, et est excellente pour améliorer la peau et prévenir l'apparition du vieillissement.
PCT/JP2017/035121 2016-09-29 2017-09-28 Agent d'amélioration du microbiote intestinal et composition d'amélioration du microbiote intestinal qui comprend une poudre contenant une membrane de coquille d'œuf WO2018062354A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2016190536A JP7086517B2 (ja) 2016-09-29 2016-09-29 卵殻膜含有粉末を有効成分として含む腸内フローラ改善用組成物
JP2016-190537 2016-09-29
JP2016-190536 2016-09-29
JP2016190537A JP2018052855A (ja) 2016-09-29 2016-09-29 卵殻膜含有粉末を含む腸内フローラ改善剤

Publications (1)

Publication Number Publication Date
WO2018062354A1 true WO2018062354A1 (fr) 2018-04-05

Family

ID=61760891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/035121 WO2018062354A1 (fr) 2016-09-29 2017-09-28 Agent d'amélioration du microbiote intestinal et composition d'amélioration du microbiote intestinal qui comprend une poudre contenant une membrane de coquille d'œuf

Country Status (1)

Country Link
WO (1) WO2018062354A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108991521A (zh) * 2018-08-10 2018-12-14 西北农林科技大学 一种肠道保护剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046006A (ja) * 2008-08-21 2010-03-04 Yukio Hasebe 卵殻膜粉末を含有する飲料
JP2013216652A (ja) * 2012-03-14 2013-10-24 Yukio Hasebe 卵殻膜含有微粉末、錠剤、卵殻膜含有微粉末の製造方法および錠剤の製造方法
WO2016066718A1 (fr) * 2014-10-28 2016-05-06 Biovotec As Particules de membrane de coquille d'œuf micronisée et leur utilisation pour favoriser la cicatrisation des plaies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046006A (ja) * 2008-08-21 2010-03-04 Yukio Hasebe 卵殻膜粉末を含有する飲料
JP2013216652A (ja) * 2012-03-14 2013-10-24 Yukio Hasebe 卵殻膜含有微粉末、錠剤、卵殻膜含有微粉末の製造方法および錠剤の製造方法
WO2016066718A1 (fr) * 2014-10-28 2016-05-06 Biovotec As Particules de membrane de coquille d'œuf micronisée et leur utilisation pour favoriser la cicatrisation des plaies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASEBE, YUKIO, THE SECRET OF ''EGGSHELL MEMBRANE, 29 June 2009 (2009-06-29), pages 120 - 126, ISBN: 9784861303920 *
HASEBE, YUKIO: "Special Interview : Elucidate the science of eggshell membrane : A new beginning in the beauty and heal field", FOOD STYLE 21, vol. 19, no. 4, 2015, pages 8 - 11, ISSN: 1343-9502 *
POLAND , A. L . ET AL.: "Altering the thermal resistance of foodborne bacterial pathogens with an eggshell membrane waste by-product", J FOOD PROTECTION, vol. 64, no. 4, 2001, pages 486 - 492, ISSN: 0362-028X *
SHI Y. ET AL.: "Hydrolysate from eggshell membrane ameliorates intestinal inflammation in mice", INT. J. MOL. SCI., vol. 15, 2014, pages 22728 - 22742, XP055498604, ISSN: 1422-0067 *
YANO, SOSUKE, A TECHNICAL JOURNAL ON FOOD CHEMISTRY & CHEMICALS, vol. 19, no. 5, 2003, pages 32 - 35, ISSN: 0911-2286 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108991521A (zh) * 2018-08-10 2018-12-14 西北农林科技大学 一种肠道保护剂及其应用

Similar Documents

Publication Publication Date Title
Kostić et al. The application of pollen as a functional food and feed ingredient—the present and perspectives
JP6122667B2 (ja) 卵殻膜含有微粉末、錠剤、卵殻膜含有微粉末の製造方法および錠剤の製造方法
KR101460998B1 (ko) 난각막성분을 포함한 간보호제 및 이 간보호제를 이용한 의약조성물, 식품첨가물 및 식품
US20160303021A1 (en) Composition comprising collagen peptide, elastin peptide and proteoglycan
KR20110031958A (ko) 장내 환경 개선제
CN111249347A (zh) 解酒护肝组合物及产品
FR2999428A1 (fr) Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
JP2014019660A (ja) 活性酸素抑制剤
JP2010077039A (ja) 免疫賦活剤または抗アレルギー剤
JPWO2008126367A1 (ja) 精神安定剤および機能性食品
WO2018062354A1 (fr) Agent d'amélioration du microbiote intestinal et composition d'amélioration du microbiote intestinal qui comprend une poudre contenant une membrane de coquille d'œuf
JP6619153B2 (ja) 青汁
JP7086517B2 (ja) 卵殻膜含有粉末を有効成分として含む腸内フローラ改善用組成物
JP5156330B2 (ja) 脂肪組織重量減少剤
JP7040898B2 (ja) 加水分解卵殻膜成分を有効成分とするｉｉｉ型コラーゲン生成促進用経口組成物
JP2003304845A (ja) 飲料または食品
KR20130103406A (ko) 난각막 함유 미분말, 정제, 난각막 함유 미분말의 제조방법 및 정제의 제조방법
WO2021074807A1 (fr) Supplément nutritionnel
JP2018052855A (ja) 卵殻膜含有粉末を含む腸内フローラ改善剤
Lepczyński et al. Antibiotics in avian care and husbandry-status and alternative antimicrobials
JP6558793B2 (ja) アトピー性皮膚炎の予防治療用組成物、並びに当該予防治療用組成物を配合してなる医薬組成物、化粧料組成物及び機能性食品
JP2018009038A (ja) 経口用組成物
JP2005239550A (ja) 疲労予防・疲労回復剤
TW201713357A (zh) 抗肥胖用組成物
WO2022058955A1 (fr) Granulé d'avocat fermenté et compléments alimentaires le contenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17856303

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17856303

Country of ref document: EP

Kind code of ref document: A1